COMP <GO>
MIRM vs JNJ // OPERATING MARGIN
Mirum Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MIRM 3
— JNJ 9
▲ OPERATING MARGIN LEADER: JNJ
LAST: $85.00 (-1.61%) • MKT CAP: $5.61B
operating-margins
-4.20%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
operating-margins
34.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MIRM VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MIRM | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.90% | 25.50% | -29.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.98% | 2.97% | -1.99 | JNJ | /fcf-yield <GO> |
| Operating Margin ACTIVE | -4.20% | 34.70% | -38.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -4.50% | 28.50% | -33.00 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 54.70% | 6.00% | +48.70 | MIRM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.29 | 5.59 | +0.70 | MIRM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | MIRM | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 60.4 | -11.66 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.08 | -0.09 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 23.0x | +9.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.61B | $662.49B | -$656.88B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MIRM REV | JNJ REV | MIRM GROSS % | JNJ GROSS % | MIRM FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $521.3M | $94.19B | 44.0% | 67.9% | $54.9M | $19.70B |
| FY 2024 | $336.9M | $88.82B | 44.0% | 69.1% | $9.3M | $19.84B |
| FY 2023 | $186.4M | $85.16B | 44.0% | 44.0% | -$79.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MIRM // BETA 0.99
JNJ // BETA 1.08